Growth rate-corrected (GR) dose-response metrics across a panel of 71 breast cancer cell lines treated with a library of small molecule and antibody perturbagens. Dataset 1 of 4: Relative cell counts and normalized growth rate inhibition values across technical replicates. - Dataset (ID:20268)
Download: Excel (XLSX), Comma-separated (CSV)
| Cell | Clinical Subtype | Transcriptional Subtype | Small Molecule | Antibody | Perturbagen Target | Perturbagen Class | Perturbagen Concentration | Perturbagen Conc Unit | Biological Replicate ID | Relative Cell Count | Normalized Growth Rate Inhibition Value | Nominal Division Rate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7474.09 | 1.2451 | 1.1880 | 2.4405 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7474.09 | 0.0022 | -0.8386 | 2.4405 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7474.09 | 0.0008 | -0.8920 | 2.4405 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7475.091 | 0.9758 | 0.9819 | 2.6839 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7475.091 | 1.2883 | 1.1980 | 2.6839 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7475.091 | 1.0660 | 1.0482 | 2.6839 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7475.091 | 1.2304 | 1.1606 | 2.6839 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 7475.091 | 1.3834 | 1.2571 | 2.6839 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 7475.091 | 1.3840 | 1.2575 | 2.6839 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 7475.091 | 1.3280 | 1.2229 | 2.6839 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 7475.091 | 0.0009 | -0.8516 | 2.6839 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 7475.091 | 0.0009 | -0.8516 | 2.6839 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 10379.092 | 0.9297 | 0.9443 | 2.5811 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 10379.092 | 0.9174 | 0.9343 | 2.5811 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 10379.092 | 0.9127 | 0.9305 | 2.5811 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 10379.092 | 0.9559 | 0.9653 | 2.5811 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 0.904 | uM | 10379.092 | 0.8934 | 0.9146 | 2.5811 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 4.52 | uM | 10379.092 | 0.8655 | 0.8912 | 2.5811 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 22.6 | uM | 10379.092 | 0.5933 | 0.6338 | 2.5811 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 113 | uM | 10379.092 | 0.0122 | -0.6376 | 2.5811 | |
| Hs 578T | TNBC | Basal B | Imatinib | ABL/KIT/PDGFR | nRTK | 565 | uM | 10379.092 | 0.0079 | -0.6938 | 2.5811 | |
| LY2 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00145 | uM | 7477.091 | 0.9996 | 0.9994 | 1.1485 | |
| LY2 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.00723 | uM | 7477.091 | 1.1492 | 1.2575 | 1.1485 | |
| LY2 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.0362 | uM | 7477.091 | 1.2487 | 1.4268 | 1.1485 | |
| LY2 | HR+ | Luminal | Imatinib | ABL/KIT/PDGFR | nRTK | 0.181 | uM | 7477.091 | 1.0516 | 1.0896 | 1.1485 |